Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Average Rating of “Buy” from Analysts

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN) have been given an average recommendation of “Buy” by the five analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $59.00.

A number of brokerages recently weighed in on AVLN. Jefferies Financial Group began coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $52.00 target price for the company. Morgan Stanley began coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 target price for the company. Guggenheim began coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $80.00 target price for the company. Wall Street Zen upgraded shares of Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Finally, Evercore initiated coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price objective for the company.

Insider Buying and Selling at Avalyn Pharma

In other Avalyn Pharma news, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the stock in a transaction on Friday, May 1st. The stock was acquired at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the transaction, the insider directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This trade represents a 34.06% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jill Carroll acquired 277,778 shares of the stock in a transaction on Friday, May 1st. The shares were acquired at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the transaction, the director directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. The trade was a 14.55% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Avalyn Pharma Stock Up 4.8%

Shares of NASDAQ:AVLN opened at $32.97 on Tuesday. Avalyn Pharma has a fifty-two week low of $24.15 and a fifty-two week high of $33.19.

Avalyn Pharma (NASDAQ:AVLN) last issued its earnings results on Wednesday, June 3rd. The company reported ($21.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45).

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.